The impact of sirolimus on hepatocyte proliferation after living donor liver transplantation

Clinical Transplantation

Volumn 24, Issue 5, 2010, Pages 695-700

  Toso, Christian ^a   Patel, Seema ^a   Asthana, Sonal ^a   Kawahara, Toshiyasu ^a   Girgis, Safwat ^b   Kneteman, Norman N ^a   Shapiro, A M James ^a   Bigam, David L ^a  

^a Pancreatic and Transplant Surgery   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Donor; Hepatocyte; Live; Liver; Proliferation; Regeneration; Sirolimus

Indexed keywords

DACLIZUMAB; KI 67 ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL; LIVER PARENCHYMA; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CELLS, CULTURED; FEMALE; GRAFT REJECTION; HEPATOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER REGENERATION; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650445766     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01159.x     Document Type: Article

References (21)

1. Morard I, Dumortier J, Spahr L et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007: 13: 658.
2. Toso C, Meeberg GA, Bigam DL et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007: 83: 1162.
3. Kneteman NM, Oberholzer J, Al SM et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004: 10: 1301.
4. Watson CJ, Friend PJ, Jamieson NV et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999: 67: 505.
5. McAlister VC, Peltekian KM, Malatjalian DA et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001: 7: 701.
6. Pridohl O, Heinemann K, Hartwig T et al. Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. Transplant Proc 2001: 33: 3229.
7. Trotter JF, Wachs M, Bak T et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001: 7: 343.
8. Wiesner R, Klintmalm G, McDiarmid S, RapamuneLiver Transplant Study Group. Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients. Am J Transplant 2002: 2: 464.
9. Wiesner R. The safety and efficacy of sirolimus and low-dose tacrolimus versus tacrolimus in de novo orthotopic liver transplant recipients. Results from a pilot study. Hepatology 2002: 36: 280A.
10. Dunkelberg JC, Trotter JF, Wachs M et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003: 9: 463.
11. Guba M, Von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002: 8: 128.
12. Semela D, Piguet AC, Kolev M et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007: 46: 840.
13. Franchello A, Gilbo N, David E et al. Ischemic preconditioning of the liver as a safe and protective technique against ischemia/reperfusion injury. Am J Transplant 2009: 9: 1629.
14. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983: 31: 13.
15. Vivarelli M, Cucchetti A, La BG et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008: 248: 857.
16. Francavilla A, Carr BI, Starzl TE, Azzarone A, Carrieri G, Zeng QH. Effects of rapamycin on cultured hepatocyte proliferation and gene expression. Hepatology 1992: 15: 871.
17. Schumacher G, Oidtmann M, Rueggeberg A et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005: 11: 1420.
18. Wu YM, Joseph B, Gupta S. Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells. Hepatology 2006: 44: 410.
19. Kirimlioglu H, Kirimlioglu V, Yilmaz S, Coban S, Turkmen E, Ara C. Liver pathology and cell proliferation after calcineurin inhibitors and antiproliferative drugs following partial hepatectomy in rats. Transplant Proc 2006: 38: 622.
20. Man K, Su M, Ng KT et al. Rapamycin attenuates liver graft injury in cirrhotic recipient--the significance of down-regulation of Rho-ROCK-VEGF pathway. Am J Transplant 2006: 6: 697.
21. Maetani Y, Itoh K, Egawa H et al. Factors influencing liver regeneration following living-donor liver transplantation of the right hepatic lobe. Transplantation 2003: 75: 97.